Published in Law and Health Weekly, December 29th, 2007
"The data further demonstrate the novel characteristics of our pegylated form of SN38, as this type of response by this class of drugs in NHL models is not expected," said Jeffrey H. Buchalter, Enzon's chairman and chief executive officer. "We continue to be encouraged by the positive preclinical results and await the completion of our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly